Azaindole derivatives, process for their preparation, and their use as antitumor agents
    44.
    发明授权
    Azaindole derivatives, process for their preparation, and their use as antitumor agents 失效
    Azaindole衍生物,其制备方法及其作为抗肿瘤剂的用途

    公开(公告)号:US06335342B1

    公开(公告)日:2002-01-01

    申请号:US09597274

    申请日:2000-06-19

    IPC分类号: A61K41435

    CPC分类号: C07D471/04

    摘要: Novel 1H-pyrrolo[2,3-b]pyridines which are represented by formula (I): wherein R is a hydrogen or halogen atom or a group selected from —CN, —OH, —OCOR4, —(CH2)nNH2, —(CH2)nNHR4, —(CH2)nNHCOR4, —(CH2)nNHCONR4R5, —(CH2)nNHCOOR4, or —(CH2)nNHSO2R4, wherein n is either 0 or 1, R4 and R5 are as described in the specification; R1 is hydrogen or an optionally substituted alkyl group; R2 is an optionally substituted group selected from alkyl or aryl; R3 is hydrogen or a group selected from —CONR4R5, —COOR4, —CONHOR4, —SO2NHR4, alkylsulphonylaminocarbonyl or perfluorinated alkylsulphonylaminocarbonyl; or a pharmaceutically acceptable salt thereof, are disclosed. These compounds are useful for treating cell proliferative disorders associated with an altered cell dependent kinase activity.

    摘要翻译: 由式(I)表示的新颖的1H-吡咯并[2,3-b]吡啶:其中R是氢或卤素原子或选自-CN,-OH,-OCOR 4, - (CH 2)n NH 2, (CH2)nNHR4, - (CH2)nNHCOR4, - (CH2)nNHCONR4R5, - (CH2)nNHCOOR4或 - (CH2)nNHSO2R4,其中n为0或1,R4和R5如说明书所述; R1是氢或任选取代的烷基; R2是任选取代的选自烷基或芳基的基团; R3是氢或选自-CONR4R5,-COOR4,-CONHOR4,-SO2NHR4,烷基磺酰基氨基羰基或全氟化烷基磺酰基氨基羰基的基团; 或其药学上可接受的盐。 这些化合物可用于治疗与改变的细胞依赖性激酶活性相关的细胞增殖性疾病。

    Heterocyclyl-ergoline derivatives as 5-HT.sub.1A receptor ligands
    46.
    发明授权
    Heterocyclyl-ergoline derivatives as 5-HT.sub.1A receptor ligands 失效
    杂环基麦角灵衍生物作为5-HT1A受体配体

    公开(公告)号:US06087371A

    公开(公告)日:2000-07-11

    申请号:US125108

    申请日:1998-08-17

    CPC分类号: C07D457/02 C07D457/00

    摘要: Ergoline derivative having formula (I) wherein R.sub.1 is hydrogen atom or C.sub.1-4 alkyl group; R.sub.2 is hydrogen, chlorine, or bromine atom, methyl or C.sub.1-4 alkylthio group; n is 0, 1 or 2; the substituent at position 8 is in .alpha. or .beta. configuration; Het represents an aromatic 5-membered heterocyclic ring, said ring having three heteroatoms which are the same or different and which are selected from the group consisting of sulfur, oxygen and nitrogen atom and X is hydrogen, chlorine or bromine or fluorine atom, or a pharmaceutically acceptable acid addition salt thereof are active at the Central Nervous System level. A process for their preparation is also described, as are pharmaceutical compositions containing them. ##STR1##

    摘要翻译: PCT No.PCT / EP97 / 00582 Sec。 371日期1998年8月17日 102(e)日期1998年8月17日PCT 1997年2月7日提交PCT公布。 公开号WO97 / 30050 PCT 日期:1997年8月21日具有式(I)的衍生物,其中R 1为氢原子或C 1-4烷基; R2是氢,氯或溴原子,甲基或C1-4烷硫基; n为0,1或2; 位置8处的取代基是α或β构型; Het表示芳族5元杂环,所述环具有三个相同或不同的杂原子,选自硫,氧和氮原子,X是氢,氯或溴或氟原子,或 其药学上可接受的酸加成盐在中枢神经系统水平上是有活性的。 还描述了其制备方法,以及含有它们的药物组合物。

    Imidazolylalkyl derivatives of imidazo�1,5-a!indol-3-one
    47.
    发明授权
    Imidazolylalkyl derivatives of imidazo�1,5-a!indol-3-one 失效
    咪唑并[1,5-a]吲哚-3-酮的咪唑基烷基衍生物

    公开(公告)号:US5874457A

    公开(公告)日:1999-02-23

    申请号:US578550

    申请日:1996-01-24

    CPC分类号: C07D487/04 Y02P20/55

    摘要: Novel 5-HT.sub.3 receptor antagonist compounds having following formula (I) ##STR1## wherein n is 1, 2 or 3;each of R, R.sub.1 and R.sub.2, which may be the same or different, is hydrogen, halogen, hydroxy, cyano, C.sub.1 -C.sub.6 alkyl, CF.sub.3, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkylthio, formyl, C.sub.2 -C.sub.6 alkanoyl, carboxy, C.sub.1 -C.sub.6 alkoxy-carbonyl, nitro, --N (R.sub.4 R.sub.5) in which each of R.sub.4 and R.sub.5 independently is hydrogen, C.sub.1 -C.sub.6 alkyl, formyl or C.sub.2 -C.sub.6 alkanoyl; or a (R.sub.6 R.sub.7) N--SO.sub.2 group, in which each of R.sub.6 and R.sub.7 independently is hydrogen or C.sub.1 -C.sub.6 alkyl;R.sub.3 is an imidazolyl group of formula ##STR2## wherein each of R.sub.8 and R.sub.10 which may be the same or different is hydrogen or C.sub.1 -C.sub.6 alkyl, R.sub.9 is hydrogen, C.sub.1 -C.sub.6 alkyl or a nitrogen protecting group; and the pharmaceutically acceptable salts thereof, are disclosed.

    摘要翻译: PCT No.PCT / EP95 / 01651 Sec。 371日期:1996年1月24日 102(e)日期1996年1月24日PCT 1995年5月2日PCT PCT。 出版物WO95 / 32204 日期:1995年11月30日具有下式(I)的新型5-HT 3受体拮抗剂化合物其中n为1,2或3; R,R 1和R 2可以相同或不同,为氢,卤素,羟基,氰基,C 1 -C 6烷基,CF 3,C 1 -C 6烷氧基,C 1 -C 6烷硫基,甲酰基,C 2 -C 6烷酰基,羧基 ,其中R 4和R 5各自独立地为氢,C 1 -C 6烷基,甲酰基或C 2 -C 6烷酰基的C 1 -C 6烷氧羰基,硝基,-N(R 4 R 5) 或(R6R7)N-SO2基团,其中R6和R7各自独立地为氢或C1-C6烷基; R 3是式(I)的咪唑基,其中R 8和R 10各自可以相同或不同,是氢或C 1 -C 6烷基,R 9是氢,C 1 -C 6烷基或氮保护基; 及其药学上可接受的盐。

    Substituted kynurenines and process for their preparation
    48.
    发明授权
    Substituted kynurenines and process for their preparation 失效
    替代的犬尿苷及其制备方法

    公开(公告)号:US5786508A

    公开(公告)日:1998-07-28

    申请号:US411656

    申请日:1995-04-06

    CPC分类号: C07C229/36 C07C2101/14

    摘要: The present invention relates to the use in the treatment of cognitive disorders associated with the aging processes of the brain and perinatal brain disorders of compounds which act as inhibitors of the enzyme kynurenine aminotransferase (KAT). The present invention also provides, as novel compounds, a selected class of KAT inhibitors which are the compounds of formula (IA) ##STR1## wherein R is halogen, C.sub.1 -C.sub.6 alkyl, C.sub.5 -C.sub.7 cycloalkyl, phenyl-C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.6 -C.sub.10 aryloxy, phenyl-C.sub.1 -C.sub.4 alkoxy or trifluoromethyl, and R.sub.1 is hydroxy, C.sub.1 -C.sub.6 alkoxy, amino, mono-C.sub.1 -C.sub.6 alkylamino, di-C.sub.1 -C.sub.6 alkylamino, hydroxylamino, C.sub.1 -C.sub.4 alkoxyamino or benzyloxyamino, with the provisos that: (i) when R.sub.1 is hydroxy and, at the same time, R is halogen, then this halogen is not fluorine; and (ii) when R.sub.1 is hydroxy and, at the same time, R is C.sub.1 -C.sub.6 alkyl, then this C.sub.1 -C.sub.6 alkyl is not methyl, either as a single isomer or as a mixture of isomers, and the pharmaceutically acceptable salts thereof.

    摘要翻译: PCT No.PCT / US94 / 07804 Sec。 371日期:1995年4月6日 102(e)日期1995年4月6日PCT 1994年7月15日PCT公布。 公开号WO95 / 04714 日期1995年2月16日本发明涉及用作治疗与作为犬尿氨酸转氨酶(KAT)酶抑制剂的化合物的脑老化过程和围产期脑疾病相关的认知障碍的用途。 本发明还提供作为新化合物的选择类别的作为式(IA)化合物的KAT抑制剂,其中R是卤素,C 1 -C 6烷基,C 5 -C 7环烷基,苯基-C 1 -C 4烷基, C 1 -C 6烷氧基,C 6 -C 10芳氧基,苯基-C 1 -C 4烷氧基或三氟甲基,R 1是羟基,C 1 -C 6烷氧基,氨基,单-C 1 -C 6烷基氨基,二-C 1 -C 6烷基氨基,羟基氨基,C 1 -C 4 烷氧基氨基或苄氧基氨基,条件是:(ⅰ)当R 1为羟基,同时R为卤素时,该卤素不为氟; 和(ii)当R 1是羟基,并且同时R是C 1 -C 6烷基时,则该C 1 -C 6烷基不是甲基,作为单一异构体或作为异构体的混合物,以及其药学上可接受的盐 。

    Substituted (arylalkoxybenzyl)aminopropanamide derivatives and process
for their preparation
    49.
    发明授权
    Substituted (arylalkoxybenzyl)aminopropanamide derivatives and process for their preparation 失效
    取代(芳基烷氧基苄基)氨基丙酰胺衍生物及其制备方法

    公开(公告)号:US5446066A

    公开(公告)日:1995-08-29

    申请号:US215628

    申请日:1994-03-22

    CPC分类号: C07C237/00

    摘要: The invention provides new compounds of formula (I) ##STR1## wherein, subject to a proviso, n is zero or an integer of 1 to 3; each of R and R.sub.1, which may be the same or different, is hydrogen, halogen, trifluoromethyl or C.sub.1 -C.sub.4 alkoxy; R.sub.2 is hydrogen or C.sub.1 -C.sub.4 alkyl optionally substituted by hydroxy; each of R.sub.3 and R.sub.4 independently is hydrogen or C.sub.1 -C.sub.4 alkyl; or a pharmaceutically acceptable salt thereof; and of formula (IA) ##STR2## wherein R.sub.5 is hydrogen, halogen, trifluoromethyl or C.sub.1 -C.sub.4 alkoxy, or a pharmaceutically acceptable salt thereof, which are active on the central nervous system (CNS) and can be used in therapy as anti-epileptics, anti-Parkinson, neuroprotective, antidepressant, anti-spastic and hypnotic agents.

    摘要翻译: 本发明提供新的式(I)化合物其中,条件是n为0或1〜3的整数; R和R 1可以相同或不同,为氢,卤素,三氟甲基或C 1 -C 4烷氧基; R2是氢或任选被羟基取代的C 1 -C 4烷基; R 3和R 4各自独立地是氢或C 1 -C 4烷基; 或其药学上可接受的盐; 和式(IA)的化合物(IA)其中R5是氢,卤素,三氟甲基或C1-C4烷氧基,或其药学上可接受的盐,其在中枢神经系统(CNS)上是有活性的并且可以用于治疗 作为抗癫痫药,抗帕金森综合征,神经保护药,抗抑郁药,抗痉挛药和催眠药。